摘要
目的评价恩必普(NBP)对急性脑梗死临床疗效、安全性及对患者血清高敏C-反应蛋白(hs-CRP)的影响。方法选择2007年1月—2008年8月山西医科大学第二医院神经内科收治的急性脑梗死患者98例,随机分为治疗组和对照组。两组基础治疗相同,治疗组加用恩必普200mg,每日4次口服。第14天、第21天、第28天时评定两组总疗效,采用NIHSS评分和日常生活活动(ADL)量表Bathel指数评价神经功能恢复情况。分别在确诊后24h内和治疗7d、14d、28d时测定血清hs-CRP,另选40名健康体检者检测血清hs-CRP为正常组。结果治疗组14d、21d、28d的NIHSS评分与对照组比较有统计学意义(P<0.05或P<0.01),两组NIHSS评分治疗后较治疗前均有统计学意义(P<0.05或P<0.01);治疗组治疗后7d、14d、28dADL评分与对照组比较有统计学意义(P<0.01),两组Bathel指数评分治疗后较治疗前均有统计学意义(P<0.01)。急性脑梗死患者血清hs-CRP浓度明显高于正常组,治疗组、对照组与正常组比较差异有统计学意义(P<0.01);治疗7d、14d后,治疗组hs-CRP下降幅度低于对照组(P<0.01)。结论恩必普可用于治疗急性脑梗死,能有效改善神经功能缺损及日常生活能力;早期应用恩必普可以显著降低急性脑梗死患者血清hs-CRP浓度,减轻炎症反应,对改善脑梗死病情及预后具有重要价值。
Objective To assess the curative effect of dl - 3 - butylphthalide（NBP） in acute cerebral infarction and its effect on serum high - sensitivity C - reactive protein（hs - CRP）. Methods Ninety - six patients（pts） with acute cerebral infarction were randomly divided into NBP group treated by NBP and conventional treatment group（control groups）. NIHSS score and activities of daily living （ADL） scale Bathel index and Serum hs - CRP were assessed at 14 days, 21 days and 28 days. Results NIHSS score in NBP group was significantly different compared with the control group at 14 days, 21 days, 28 days（P〈0.05 or P〈0.01） ; Bathel index score in NBP group was significant different compared with control group at 28 day（P〈0.01）. Serum concentration of hs - CRP in pts was significantly higher than that in normal group. Following treatment for 7 days, 14 days, hs -CRP in NBP group was less than that in control group（P〈0.01）. Conclusion NBP could effectively improve the neurological deficits and daily activities in pts with acute cerebral infarction.
出处
《中西医结合心脑血管病杂志》
2009年第2期161-163,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
脑梗死
恩必普
高敏C反应蛋白
acute cerebral infarction
d1 - 3 - butylphthalide
hs - CRP
